DK3511004T3 - Kombineret præparat til behandling af cancer - Google Patents

Kombineret præparat til behandling af cancer Download PDF

Info

Publication number
DK3511004T3
DK3511004T3 DK19158672.6T DK19158672T DK3511004T3 DK 3511004 T3 DK3511004 T3 DK 3511004T3 DK 19158672 T DK19158672 T DK 19158672T DK 3511004 T3 DK3511004 T3 DK 3511004T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
combined preparation
preparation
combined
Prior art date
Application number
DK19158672.6T
Other languages
Danish (da)
English (en)
Inventor
Frédéric Triebel
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immutep Sas filed Critical Immutep Sas
Application granted granted Critical
Publication of DK3511004T3 publication Critical patent/DK3511004T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK19158672.6T 2013-12-19 2014-12-19 Kombineret præparat til behandling af cancer DK3511004T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1322626.1A GB201322626D0 (en) 2013-12-19 2013-12-19 Combined preparations for the treatment of cancer
EP14830806.7A EP3089749B1 (en) 2013-12-19 2014-12-19 Combined preparations for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3511004T3 true DK3511004T3 (da) 2024-09-23

Family

ID=50071175

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19158672.6T DK3511004T3 (da) 2013-12-19 2014-12-19 Kombineret præparat til behandling af cancer
DK14830806.7T DK3089749T3 (da) 2013-12-19 2014-12-19 Kombinerede præparater til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14830806.7T DK3089749T3 (da) 2013-12-19 2014-12-19 Kombinerede præparater til behandling af cancer

Country Status (14)

Country Link
US (3) US10736940B2 (enExample)
EP (3) EP4414035A3 (enExample)
JP (2) JP6691054B2 (enExample)
KR (3) KR102441425B1 (enExample)
CN (2) CN112957452A (enExample)
AU (1) AU2014368420B2 (enExample)
DK (2) DK3511004T3 (enExample)
ES (2) ES2986949T3 (enExample)
FI (1) FI3511004T3 (enExample)
GB (1) GB201322626D0 (enExample)
PL (2) PL3089749T3 (enExample)
PT (2) PT3089749T (enExample)
TR (1) TR201910866T4 (enExample)
WO (1) WO2015091970A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US10265379B2 (en) * 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
MA43576A (fr) 2015-12-16 2018-11-14 Merck Sharp & Dohme Anticorps anti-lag3 et fragments de fixation à l'antigène
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
MY200034A (en) 2017-02-10 2023-12-05 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
EP4157879A4 (en) * 2020-05-27 2024-06-19 Agilent Technologies, Inc. Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc)
US20230210946A1 (en) * 2020-05-28 2023-07-06 Immutep S.A.S. Treatment of cancer

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5539084A (en) 1989-02-17 1996-07-23 Coselco Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US7294712B2 (en) 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1992005262A1 (en) 1990-09-14 1992-04-02 The John Hopkins University Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
JP3459268B2 (ja) * 1990-09-17 2003-10-20 中外製薬株式会社 抗癌剤
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
IE920413A1 (en) 1991-02-08 1992-08-12 Roussel Uclaf Nucleotide sequence coding for ó-chain variable regions of¹human t-lymphocyte receptors, corresponding peptide segments¹and diagnostic and therapeutic applications
KR100227303B1 (ko) 1991-02-12 1999-12-01 장-끌로드 비에이으포스 인체 t 임파구 수용체의 베타 사슬의 가변성 영역을 코딩하는 뉴클레오티드 서열, 대응하는 펩티드 세그먼트 및 진단 및 치료 용도
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US6506604B2 (en) 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
CN1110557C (zh) 1994-05-06 2003-06-04 古斯达威罗斯研究所 Lag－3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
JP2000516101A (ja) 1996-11-28 2000-12-05 アンスティテュ ギュスタブ ルシ Ｌａｇ−３タンパク質の変異体、その発現及び使用
BR9612821A (pt) 1996-11-29 2000-04-11 Applied Research Systems Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
CA2287478C (en) 1997-04-14 2007-06-19 Richard J. Samulski Methods for increasing the efficiency of recombinant aav product
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6037177A (en) 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
KR20010074426A (ko) 1998-02-02 2001-08-04 추후제출 만능 면역조절 사이토킨-발현 방관자 세포주 및 관련조성물 및 제조방법 및 사용방법
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
AT409086B (de) 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
JP2004508290A (ja) 2000-04-26 2004-03-18 バイオベクター　セラピューティクス 免疫調節における粒状ベクターの使用
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ATE519779T1 (de) 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
SI1505973T1 (sl) * 2002-05-17 2010-06-30 Celgene Corp Kombinacija za zdravljenje multiplega mieloma
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
MXPA06003977A (es) 2003-10-10 2006-06-27 Powderject Vaccines Inc Metodo.
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
JP2006124383A (ja) 2004-09-30 2006-05-18 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
JP2006141346A (ja) 2004-11-24 2006-06-08 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US20070231298A1 (en) 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009032256A2 (en) 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2648734B1 (en) 2010-12-06 2019-02-13 Cure Cancer Worldwide LLC Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
RU2563346C2 (ru) 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2015512616A (ja) 2012-02-01 2015-04-30 コンピュゲン エルティーディー． Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
PL3508502T3 (pl) 2013-09-20 2023-07-17 Bristol-Myers Squibb Company Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015131176A1 (en) 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Also Published As

Publication number Publication date
CN112957452A (zh) 2021-06-15
PT3511004T (pt) 2024-09-03
CN105916504B (zh) 2021-03-23
ES2986949T3 (es) 2024-11-13
EP3089749A1 (en) 2016-11-09
US10736940B2 (en) 2020-08-11
EP3511004A1 (en) 2019-07-17
FI3511004T3 (fi) 2024-09-25
JP6691054B2 (ja) 2020-05-20
WO2015091970A1 (en) 2015-06-25
EP3089749B1 (en) 2019-05-22
KR102593917B1 (ko) 2023-10-26
EP4414035A3 (en) 2024-08-21
AU2014368420B2 (en) 2019-03-07
KR20220054915A (ko) 2022-05-03
PT3089749T (pt) 2019-09-06
US12214012B2 (en) 2025-02-04
KR102441425B1 (ko) 2022-09-08
CN105916504A (zh) 2016-08-31
US20160310570A1 (en) 2016-10-27
PL3089749T3 (pl) 2019-11-29
JP2017503014A (ja) 2017-01-26
PL3511004T3 (pl) 2024-11-12
EP4414035A2 (en) 2024-08-14
DK3089749T3 (da) 2019-08-26
EP3511004B1 (en) 2024-07-03
GB201322626D0 (en) 2014-02-05
US20250127856A1 (en) 2025-04-24
JP2019203035A (ja) 2019-11-28
KR20220108215A (ko) 2022-08-02
US20200323957A1 (en) 2020-10-15
TR201910866T4 (tr) 2019-08-21
JP7160345B2 (ja) 2022-10-25
AU2014368420A1 (en) 2016-07-07
KR20160093076A (ko) 2016-08-05
ES2730976T3 (es) 2019-11-13

Similar Documents

Publication Publication Date Title
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK2968208T3 (da) Behandling af kataplexi
HUE059694T2 (hu) Készítmény rák kezelésére
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3511004T3 (da) Kombineret præparat til behandling af cancer
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
PT2953948T (pt) Antagonistas de integrina fluorada
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
HRP20181122T1 (hr) Postupak za pripremu jopamidola
LT3563837T (lt) Terapija bakteriofagu
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3016682T3 (da) Metoder til behandling af kræft